ATE437652T1 - Verwendung von hmgb1 zur aktivierung dendritischer zellen - Google Patents

Verwendung von hmgb1 zur aktivierung dendritischer zellen

Info

Publication number
ATE437652T1
ATE437652T1 AT02775057T AT02775057T ATE437652T1 AT E437652 T1 ATE437652 T1 AT E437652T1 AT 02775057 T AT02775057 T AT 02775057T AT 02775057 T AT02775057 T AT 02775057T AT E437652 T1 ATE437652 T1 AT E437652T1
Authority
AT
Austria
Prior art keywords
hmgb1
dendritic cells
activate dendritic
activate
apc
Prior art date
Application number
AT02775057T
Other languages
English (en)
Inventor
Marco Bianchi
Angelo Manfredi
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Application granted granted Critical
Publication of ATE437652T1 publication Critical patent/ATE437652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02775057T 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen ATE437652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene
PCT/IB2002/004080 WO2003026691A2 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells

Publications (1)

Publication Number Publication Date
ATE437652T1 true ATE437652T1 (de) 2009-08-15

Family

ID=11448420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775057T ATE437652T1 (de) 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen

Country Status (9)

Country Link
US (1) US20040242481A1 (de)
EP (1) EP1432441B1 (de)
JP (1) JP2005508913A (de)
AT (1) ATE437652T1 (de)
AU (1) AU2002341266B2 (de)
CA (1) CA2461091A1 (de)
DE (1) DE60233147D1 (de)
IT (1) ITMI20011986A1 (de)
WO (1) WO2003026691A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1899376A2 (de) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antikörper gegen hmgb 1 und fragmente davon
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
CA2636788A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Hmgb protein for use in promoting tissue regeneration
TW200900077A (en) 2007-02-15 2009-01-01 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
WO2008099917A1 (ja) * 2007-02-15 2008-08-21 Fukuoka University 抗hmgb-1抗体を含む臓器移植拒絶抑制剤
HUE047164T2 (hu) 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
JP5814549B2 (ja) * 2008-04-30 2015-11-17 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
RU2519714C2 (ru) * 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
CA2787661C (en) 2010-01-21 2021-10-12 The Board Of Trustees Of The University Of Arkansas Vaccine vectors and methods of enhancing immune responses
US8999291B2 (en) 2010-03-29 2015-04-07 University Of Southern California Compositions and methods for the removal of biofilms
EP3556397A1 (de) * 2010-06-09 2019-10-23 The Board of Trustees of the University of Arkansas Impfstoff und verfahren zur linderung einer campylobacter-infektion
US20120128701A1 (en) * 2010-09-09 2012-05-24 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
EP2703487B1 (de) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide zur induktion der regenerierung von gewebe und verwendung davon
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
SG11201503236RA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating cardiac infarction using hmgb1 fragment
CN104955470B (zh) 2012-10-25 2017-06-16 吉诺米克斯股份有限公司 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
PL2956165T3 (pl) 2013-02-14 2020-04-30 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi immunologicznych na Eimeria lub ograniczania infekcji Eimeria
EA033538B1 (ru) 2013-03-15 2019-10-31 Univ Arkansas Композиции и способы усиления иммунного ответа на кишечные патогены
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
JP2018528763A (ja) 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体
GB201600075D0 (en) 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
US10682398B2 (en) 2016-05-03 2020-06-16 The Texas A&M University System Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
CA3051825A1 (en) 2017-01-27 2018-08-02 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis

Also Published As

Publication number Publication date
WO2003026691A3 (en) 2003-05-30
US20040242481A1 (en) 2004-12-02
EP1432441A2 (de) 2004-06-30
WO2003026691A2 (en) 2003-04-03
EP1432441B1 (de) 2009-07-29
ITMI20011986A0 (it) 2001-09-25
CA2461091A1 (en) 2003-04-03
ITMI20011986A1 (it) 2003-03-25
AU2002341266B2 (en) 2007-11-15
DE60233147D1 (de) 2009-09-10
JP2005508913A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
DK1525320T3 (da) Fremgangsmåde til ekspression af rekombinant protein i CHO-celler
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
NO2011003I2 (de)
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
ATE530643T1 (de) Säureaktive fungale protease
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
CY1109207T1 (el) Διαδικασια εχινοκανδινης
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DE69535696D1 (de) Tripeptidyl-aminopeptidase
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
DK1344827T3 (da) Frostbeskyttende proteiner fra basidiomycetes
DK1145012T3 (da) Fremgangsmåder og kits til sekventering af polypeptider
DE60332579D1 (de) Prozess zur Immobilisierung von Polypeptiden über die Carboxylgruppe des C-terminus
ATE391727T1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
ATE393213T1 (de) Dendritische zelle mit alpha-glycosylceramid- derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen
SE0101519D0 (sv) Nucleic ACID

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties